NCT04712851View on ClinicalTrials.gov

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Cervical Intraepithelial NeoplasiaCervical Squamous Cell Carcinoma In SituCervical Squamous Intraepithelial Neoplasia 2
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

90095

RECRUITING

University of California at Los Angeles / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT04712851 - Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | Biotech Hunter | Biotech Hunter